ScholarWorks@Korea University College of Medicine

The Lancet Oncology

Journal Title

  • The Lancet Oncology

ISSN

  • E 1474-5488 | P 1470-2045

Publisher

  • The Lancet Publishing Group

Listed on(Coverage)

JCR 2003-2019
SJR 2001-2019
CiteScore 2011-2019
SCIE 2010-2021
CC 2016-2021
SCOPUS 2017-2020
MEDLINE 2016-2021
EMBASE 2016-2020

Active

  • Active

    based on the information

    • SCOPUS:2020-10

Country

  • USA

Aime & Scopes

  • The Lancet Oncology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. As the global leader in clinical oncology research, The Lancet Oncology delivers essential original research, expert review, candid commentary, and breaking news to provide context and perspective on today's most important medical advances across the broad spectrum of oncology.

Homepage

Article List

1 - 9 out of 9 results.

SCIESCOPUS
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study

Elimova, Elena; Ajani, Jaffer; Burris, Howard; Denlinger, Crystal S; Iqbal, Syma; Kang, Yoon-Koo; Kim, Jwa Hoon; Lee, Keun-Wook; Lin, Bruce; Mehta, Rutika, et al.

ArticleIssue Date2025CitationThe Lancet Oncology, v.26, no.7, pp 847 - 859PublisherThe Lancet Publishing Group
SCIESCOPUS
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study

Ahn, Hee Kyung; Kim, Ji-Yeon; Lee, Kyung-Hun; Kim, Gun Min; Kang, Seok Yun; Lee, Keun Seok; Kim, Jee Hyun; Lee, Kyong Eun; Lee, Moon Hee; Kim, Hee-Jun, et al.

ArticleIssue Date2025CitationThe Lancet Oncology, v.26, no.3, pp 343 - 354PublisherThe Lancet Publishing Group
SCIESCOPUS
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study

Wainberg, Zev A.; Enzinger, Peter C.; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet, et al.

ArticleIssue Date2022CitationThe Lancet Oncology, v.23, no.11, pp 1430 - 1440PublisherThe Lancet Publishing Group
SCIESCOPUS
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Kang, Yoon-Koo; Chen, Li-Tzong; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Chung, Hyun Cheol; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi, et al.

ArticleIssue Date2022CitationThe Lancet Oncology, v.23, no.2, pp 234 - 247PublisherThe Lancet Publishing Group
SCIESCOPUS
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Youn, Jin Won; Hur, Soo-Young; Woo, Jung Won; Kim, Yong-Man; Lim, Myong Cheol; Park, Sang Yoon; Seo, Sang Soo; No, Jae Hong; Kim, Byoung-Gie; Lee, Jae-Kwan, et al.

ArticleIssue Date2020CitationThe Lancet Oncology, v.21, no.12, pp 1653 - 1660PublisherThe Lancet Publishing Group
SCIESCOPUS
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial

Catenacci, Daniel V. T.; Kang, Yoon-Koo; Park, Haeseong; Uronis, Hope E.; Lee, Keun-Wook; Ng, Matthew C. H.; Enzinger, Peter C.; Park, Se Hoon; Gold, Philip J.; Lacy, Jill, et al.

ArticleIssue Date2020CitationThe Lancet Oncology, v.21, no.8, pp 1066 - 1076PublisherThe Lancet Publishing Group
SCIESCOPUS
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

Kang, Yoon-Koo; Chin, Keisho; Chung, Hyun Cheol; Kadowaki, Shigenori; Oh, Sang Cheul; Nakayama, Norisuke; Lee, Keun-Wook; Hara, Hiroki; Chung, Ik-Joo; Tsuda, Masahiro, et al.

ArticleIssue Date2020CitationThe Lancet Oncology, v.21, no.8, pp 1045 - 1056PublisherThe Lancet Publishing Group
SCIESCOPUS
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Park, Yeon Hee; Kim, Tae-Yong; Kim, Gun Min; Kang, Seok Yun; Park, In Hae; Kim, Jee Hyun; Lee, Kyoung Eun; Ahn, Hee Kyung; Lee, Moon Hee; Kim, Hee-Jun, et al.

ArticleIssue Date2019CitationThe Lancet Oncology, v.20, no.12, pp 1750 - 1759PublisherThe Lancet Publishing Group
SCIESCOPUS
Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC

Togawa, Kayo; Ahn, Hyeong Sik; Auvinen, Anssi; Bauer, Andrew J.; Brito, Juan P.; Davies, Louise; Kesminiene, Ausrele; Laurier, Dominique; Ostroumova, Evgenia; Pacini, Furio, et al.

ArticleIssue Date2018CitationThe Lancet Oncology, v.19, no.10, pp 1280 - 1283PublisherThe Lancet Publishing Group
1
CONTACT US

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어